One of the critical things is that, as I mentioned, we provide this digital service e-Therapeutics+, and we post every Health Canada advisory that becomes available, alerting physicians, pharmacists, nurses, and other prescribers to any new adverse drug reaction that's out there. We play a role in the dissemination of information.
We're also very interested in some of the proposals to look at new approaches to drug regulation that would allow a combination of strategies, where you could perhaps get drugs to the market earlier but at the same time be more effective at collecting data relating to adverse drug reactions. I think it's something that we still need to work on. I still think we have under-reporting of adverse drug reactions, but as an association we do what we can through our digital information service to make sure that prescribers have up-to-date information around adverse drug reactions, to guide their decisions.